4-benzyl-2-phenyl-1,2,4-thiadiazolidine-3,5-dione | 1111871-48-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyl-2-phenyl-1,2,4-thiadiazolidine-3,5-dione
• 英文别名: 2-phenyl-4-benzyl-1,2,4-thiadiazolidine-3,5-dione；2-phenyl-4-benzyl-1,2,4-thiadiazoline-3,5-dione
• CAS: 1111871-48-7
• 化学式: C₁₅H₁₂N₂O₂S
• 分子量: 284.338
• InChiKey: DQZXYBWDQNXAPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-benzyl-1-(N-carbonochloridoylanilino)sulfanylmethanimidoyl chloride 以 水 为溶剂， 反应 0.5h， 以75%的产率得到4-benzyl-2-phenyl-1,2,4-thiadiazolidine-3,5-dione
  参考文献：
  名称：

  1,2,4-Thiadiazolidin-3,5-diones as novel hydrogen sulfide donors

  摘要：

  Hydrogen sulfide (H2S) is an endogenous modulator that plays significant physio-pathological roles in several biological systems. In this research field there is a large interest in developing selective CBS and CSE inhibitors and H2S releasing moieties, that could be either used as therapeutic agents or linked to known drugs. One of the major problem is the limited availability of chemicals that ensure a controlled release of H2S in vitro as well in vivo. Aiming to obtain novel H2S donors, whose release properties could be appropriately modulated, we have synthesized a series of 1,2,4-thiadiazolidine-3,5-diones (THIA 1-10) as innovative donors that could release H2S in controlled manner. All the synthesized compounds were evaluated for their H2S releasing properties by an amperometric approach and for their vasorelaxant ability on aorta rings. In order to rationalize the obtained results, a detailed study on the release mechanism has been performed using the most efficient H2S donor, THIA 3 (C-max 65.4 mu M and EC50 1.7 mu M). 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.10.068

文献信息

• SMALL MOLECULE INHIBITORS OF RGS PROTEINS
  申请人：Neubig Richard

  公开号：US20120277273A1

  公开（公告）日：2012-11-01

  The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).

  该发明涉及具有RGS（G蛋白信号调节因子）抑制活性的组合物，以及其使用方法。在某些实施例中，具有RGS抑制活性的组合物可用于研究或治疗疾病状态（例如糖尿病、癫痫、神经痛、抑郁症和其他疾病）。
• Compositions and methods for treating cancers
  申请人：Cedars-Sinai Medical Center

  公开号：US10029997B2

  公开（公告）日：2018-07-24

  The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

  本发明描述了同时抑制 HDAC 和 GSK3β 的化合物（即 HDAC/GSK3β 双抑制剂）。本发明进一步描述了含有这些 HDAC/GSK3β 双抑制剂的组合物，以及使用这些 HDAC/GSK3β 双抑制剂治疗各种病症的方法和试剂盒。本发明还提供了使用 HDAC 抑制剂和 GSK3β 治疗各种病症的方法和试剂盒，以及含有 HDAC 抑制剂和 GSK3β 的组合物。本发明的各种实施方案可治疗的病症包括但不限于癌症和肿瘤。
• Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins
  作者：Emma M. Turner、Levi L. Blazer、Richard R. Neubig、Stephen M. Husbands

  DOI：10.1021/ml200263y

  日期：2012.2.9

  Recently, regulators of G protein signaling (RGS) proteins have emerged as potential therapeutic targets since they provide an alternative method of modulating the activity of G protein-coupled receptors, the target of so many drugs. Inhibitors of RGS proteins must block a protein protein interaction (RGS-G alpha) but also be cell and, depending on the therapeutic target, blood brain barrier permeable. A lead compound (la) was identified as an inhibitor of RGS4 in a screening assay, and this has now been optimized for activity, selectivity, and solubility. The newly developed ligands (11b and 13) display substantial selectivity over the closely related RGS8 protein, lack the off-target calcium mobilization activity of the lead la, and have excellent aqueous solubility. They are currently being evaluated in vivo in rodent models of depression.
• N-Chlorosuccinimide is a convenient oxidant for the synthesis of 2,4-disubstituted 1,2,4-thiadiazolidine-3,5-diones
  作者：Shama Nasim、Peter A. Crooks

  DOI：10.1016/j.tetlet.2008.10.136

  日期：2009.1

  N-Chlorosuccinimide has been identified as a convenient and safe alternative oxidant for the oxidative condensation of isothiocyanates and isocyanates to afford 1,2,4-thiadiazolidine-3,5-diones. (C) 2008 Elsevier Ltd. All rights reserved.
• COMPOSITIONS AND METHODS FOR TREATING CANCERS
  申请人：Cedars-Sinai Medical Center

  公开号：US20170121297A1

  公开（公告）日：2017-05-04

  The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.